Corporate · Global B2B
Cryophore™ Panels

Preconfigured multiplex panels with a validation-led release path.

The deck lists Release 01 panels for pleural and ascitic fluid, Release 02 FNA-tailored development, and future indication-specific panels composed by an expert committee.

Release path

Panel releases are tied to validation completion.

Release 01

Pleural Fluid 1

GATA3, Calretinin, TTF1, EpCAM, CD45, p40, Synaptophysin

Effusion panel listed in the deck as part of Release 01.

Panel details
Release 01

Pleural Fluid 2

NKX3.1, Calretinin, TTF1, EpCAM, CD45, p40, Synaptophysin

Deck-listed effusion panel for additional tumour-origin support. Availability should be confirmed with X-ZELL.

View panels
Release 01

Ascitic Fluid

PAX8, SATB2, CK19, EpCAM, CD45, Calretinin, CK7

Deck-listed ascitic fluid panel supporting malignant ascites cytology workflows.

Panel details
Release 02

FNA-tailored panels

In development

The deck describes FNA-tailored panels developed with the Institute of Oncology Ljubljana cytopathology group.

Beyond 2026

Indication-specific panels

Pipeline

Future panel releases are described as timed to clinical demand and validation completion.

Governance

Expert committee composition

No bespoke customer changes

Panel composition is described as expert-composed and not changed by individual customers.

Panels

Need current panel availability?

Panel status and intended use vary by market. Ask X-ZELL for current documentation before selection.